phibro animal health - PAHC

PAHC

Close Chg Chg %
39.44 0.39 0.99%

Pre-Market

39.83

+0.39 (0.99%)

Volume: 270.55K

Last Updated:

Jan 12, 2026, 4:00 PM EDT

Company Overview: phibro animal health - PAHC

PAHC Key Data

Open

$39.40

Day Range

38.71 - 40.36

52 Week Range

16.16 - 46.42

Market Cap

$1.62B

Shares Outstanding

40.58M

Public Float

20.30M

Beta

0.78

Rev. Per Employee

N/A

P/E Ratio

23.71

EPS

$1.67

Yield

121.70%

Dividend

$0.12

EX-DIVIDEND DATE

Nov 26, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

238.04K

 

PAHC Performance

1 Week
 
0.99%
 
1 Month
 
-0.80%
 
3 Months
 
0.28%
 
1 Year
 
91.31%
 
5 Years
 
86.47%
 

PAHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About phibro animal health - PAHC

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment focuses on the development and marketing of medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment is involved in the manufacture and marketing of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

PAHC At a Glance

Phibro Animal Health Corp.
Glenpointe Centre East
Teaneck, New Jersey 07666-6712
Phone 1-201-329-7300 Revenue 1.30B
Industry Pharmaceuticals: Major Net Income 48.26M
Sector Health Technology 2025 Sales Growth 27.37%
Fiscal Year-end 06 / 2026 Employees 2,475
View SEC Filings

PAHC Valuation

P/E Current 23.712
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 21.525
Price to Sales Ratio 0.801
Price to Book Ratio 3.624
Price to Cash Flow Ratio 12.97
Enterprise Value to EBITDA 10.327
Enterprise Value to Sales 1.33
Total Debt to Enterprise Value 0.442

PAHC Efficiency

Revenue/Employee 523,723.232
Income Per Employee 19,500.606
Receivables Turnover 5.686
Total Asset Turnover 1.106

PAHC Liquidity

Current Ratio 2.762
Quick Ratio 1.248
Cash Ratio 0.263

PAHC Profitability

Gross Margin 30.162
Operating Margin 9.357
Pretax Margin 5.246
Net Margin 3.723
Return on Assets 4.12
Return on Equity 17.799
Return on Total Capital 4.609
Return on Invested Capital 5.464

PAHC Capital Structure

Total Debt to Total Equity 266.573
Total Debt to Total Capital 72.72
Total Debt to Total Assets 55.959
Long-Term Debt to Equity 257.69
Long-Term Debt to Total Capital 70.297
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Phibro Animal Health - PAHC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
942.26M 977.89M 1.02B 1.30B
Sales Growth
+13.07% +3.78% +4.07% +27.37%
Cost of Goods Sold (COGS) incl D&A
655.42M 678.41M 705.19M 905.25M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
32.70M 34.01M 36.18M 45.60M
Depreciation
23.78M 24.32M 26.52M 37.76M
Amortization of Intangibles
8.92M 9.70M 9.66M 7.84M
COGS Growth
+16.86% +3.51% +3.95% +28.37%
Gross Income
286.84M 299.47M 312.49M 390.97M
Gross Income Growth
+5.27% +4.40% +4.35% +25.12%
Gross Profit Margin
+30.44% +30.62% +30.71% +30.16%
2022 2023 2024 2025 5-year trend
SG&A Expense
207.34M 219.50M 250.07M 269.68M
Research & Development
20.83M 24.39M 29.19M 23.73M
Other SG&A
186.51M 195.10M 220.88M 245.96M
SGA Growth
+5.51% +5.86% +13.93% +7.84%
Other Operating Expense
- - - -
-
Unusual Expense
4.62M (1.74M) (5.40M) 45.42M
EBIT after Unusual Expense
74.88M 81.72M 67.82M 75.86M
Non Operating Income/Expense
7.24M 900.00K (19.39M) (5.25M)
Non-Operating Interest Income
816.00K 3.35M 4.47M 2.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.79M 28.55M 37.51M 2.62M
Interest Expense Growth
-5.91% +191.70% +31.41% -93.01%
Gross Interest Expense
9.79M 28.55M 37.51M 2.62M
Interest Capitalized
- - - -
-
Pretax Income
72.33M 54.07M 10.92M 67.99M
Pretax Income Growth
+8.81% -25.24% -79.81% +522.87%
Pretax Margin
+7.68% +5.53% +1.07% +5.25%
Income Tax
23.15M 21.46M 8.50M 19.73M
Income Tax - Current - Domestic
6.34M 11.61M 4.75M 8.01M
Income Tax - Current - Foreign
17.61M 12.75M 15.74M 16.48M
Income Tax - Deferred - Domestic
176.00K (6.42M) (6.28M) (5.93M)
Income Tax - Deferred - Foreign
(979.00K) 3.52M (5.72M) 1.18M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
49.17M 32.61M 2.42M 48.26M
Minority Interest Expense
- - - -
-
Net Income
49.17M 32.61M 2.42M 48.26M
Net Income Growth
-9.58% -33.69% -92.59% +1,897.68%
Net Margin Growth
+5.22% +3.33% +0.24% +3.72%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
49.17M 32.61M 2.42M 48.26M
Preferred Dividends
- - - -
-
Net Income Available to Common
49.17M 32.61M 2.42M 48.26M
EPS (Basic)
1.2141 0.805 0.0596 1.1913
EPS (Basic) Growth
-9.65% -33.70% -92.60% +1,898.83%
Basic Shares Outstanding
40.50M 40.50M 40.50M 40.52M
EPS (Diluted)
1.2141 0.805 0.0596 1.1865
EPS (Diluted) Growth
-9.58% -33.70% -92.60% +1,890.77%
Diluted Shares Outstanding
40.50M 40.50M 40.52M 40.68M
EBITDA
112.21M 113.99M 98.60M 166.89M
EBITDA Growth
+4.04% +1.59% -13.50% +69.27%
EBITDA Margin
+11.91% +11.66% +9.69% +12.88%

Snapshot

Average Recommendation HOLD Average Target Price 41.00
Number of Ratings 4 Current Quarters Estimate 0.68
FY Report Date 03 / 2026 Current Year's Estimate 2.74
Last Quarter’s Earnings 0.67 Median PE on CY Estimate N/A
Year Ago Earnings 2.09 Next Fiscal Year Estimate 3.018
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.68 0.66 2.74 3.02
High Estimates 0.71 0.70 2.80 3.08
Low Estimate 0.64 0.61 2.66 2.91
Coefficient of Variance 4.33 5.61 2.21 2.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Phibro Animal Health - PAHC

Date Name Shares Transaction Value
Nov 20, 2025 BFI Co. LLC President and CEO; Director 60,240 Conversion of derivative security 0.00
Nov 20, 2025 BFI Co. LLC President and CEO; Director 54,960 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.56 per share 2,449,017.60
Nov 20, 2025 BFI Co. LLC President and CEO; Director 49,700 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.82 per share 2,177,854.00
Nov 20, 2025 BFI Co. LLC President and CEO; Director 49,680 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.28 per share 2,199,830.40
Feb 27, 2025 E. Thomas Corcoran Director 30,000 Open market or private purchase of non-derivative security Non-derivative transaction at $22.1 per share 663,000.00

Phibro Animal Health in the News